Moderna Stock Jumps on COVID-19 Vaccine Race News

By Timothy Sykes

Last updated on April 18, 2022
Moderna Stock Jumps on COVID-19 Vaccine Race News Thumbnail

Coming on the heels of the 90% effective vaccine Pfizer Inc. (NYSE: PFE) announced on Monday, there’s now news of a second vaccine that could be just as good…

Today, Moderna, Inc., (Nasdaq: MRNA) announced it’s preparing for the first analysis of its COVID-19 phase three trial.

Phase three is the final stage before FDA approval. The Moderna study has 30,000 participants, is randomized, and is placebo-controlled.

Investors reacted strongly when Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, mentioned it while speaking at the FT Live Global Pharmaceutical Summit.

Fauci said he would “be surprised if we didn’t see a similar degree of efficacy” as was reported in the Pfizer vaccine.

MRNA stock closed the day up 8.4% to close at its highest level since July 22. The move added about $2.5 billion in market cap.

To date, no vaccine has been approved by the FDA. The FDA could authorize a vaccine for emergency use as soon as next month.

Posts contain affiliate links. may get compensated for affiliate posts and purchases through links


How much has this post helped you?

star star star star star
Comments (1)
Author imageTimothy Sykes
Hey Everyone,

As many of you already know I grew up in a middle class family and didn't have many luxuries. But through trading I was able to change my circumstances --not just for me -- but for my parents as well. I now want to help you and thousands of other people from all around the world achieve similar results!

Which is why I've launched my Trading Challenge. I’m extremely determined to create a millionaire trader out of one my students and hopefully it will be you.

So when you get a chance make sure you check it out.

PS: Don’t forget to check out my 30 Day Bootcamp, it will teach you everything you need to know about trading.

Leave a Reply